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Summary This paper deals with the utility of immunoliposomes for the delivery of doxorubicin (DXR) to 
human ovarian carcinoma cells in vitro and in vivo. We aimed to investigate whether immunoliposome- 
mediated targeting of DXR to ovarian cancer cells translates in an enhanced anti-tumour effect compared with 
that of non-targe ted DXR liposomes (lacking the specific antibody). Target cell binding and anti-tumour 
activity of DXR immunoliposomes were studied in vitro and in vivo (xenograft model of ovarian carcinoma). In 
vitro we observed that target cell binding and cell growth inhibition of DXR immunoliposomes is superior to 
that of non-targeted DXR-liposomes. However, in vivo, despite the efficient target cell binding and good anti­
tumour response of DXR-immunoliposomes, no difference in anti-tumour effect, compared with non-targeted 
DXR-liposomes, could be determined. The results indicate that premature DXR leakage from immunolipo­
somes occurring before the actual target cell binding and subsequent DXR association with the tumour cells, 
explains why no significant differences in anti-tumour activity between DXR-immunoliposomes and non- 
targeted DXR-liposomes were observed in vivo.
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Ovarian cancer is associated with a high incidence and the 
highest mortality compared with other gynaecological 
malignancies. As ovarian carcinoma remains confined to the 
peritoneal cavity throughout most o f  its clinical course, this 
type o f cancer is an attractive candidate for intraperitoneal 
(i.p.) chemotherapy (Straubinger et a l., 1988; Markman, 
1991; Nassander et al., 1992). Clinical pharmacokinetic 
studies have demonstrated that i.p. administration results in 
higher concentrations of drug at the site o f disease, whereas
systemic plasma concentrations, and systemic
toxicity, remain lower than after intravenous (i.v.) adminis­
tration. Local anti-tumour activity after i.p. chemotherapy 
may therefore be expected to be higher with lower systemic
« •
toxicity.
Intraperitoneal administration o f doxorubicin (DXR), a
broad-spectrum antineoplastic agent, is greatly
hampered by local
*  *
in particular
peritonitis. Therefore, investigators did not continue to use 
DXR for i.p. chemotherapy of ovarian carcinoma (Ozols et
et al., 1985; Markman et a l ., 1989).
local 
by
al., 1982; 
Preclinical and shows
ammatory reaction produced by DXR is
encapsulation of DXR in liposomes (Forssen and Tokes, 
1981; Delgado et al., 1989). In a phase I/II trial it was shown 
that DXR-liposomes can be administered i.p. with minimal 
peritonitis up to a three times higher dose per cycle than free 
DXR (Delgado et al., 1989). Even then, maximum tolerable 
dose was not reached with DXR-liposomes.
we and others have shown that the use of  
s to direct drugs encapsulated in liposomes to 
tumours creates an interesting possibility for increasing the
and efficacy of i.p. chemotherapy of tumours 
located in the peritoneal cavity (Straubinger e t al.,
Singh et al., 1991; Nassander et al., 1992). To target the
to the tumour cells in the
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peritoneal cavity, Fab' fragments o f the monoclonal antibody 
OV-TL3, which is directed against the antigen OA3 present 
on over 90% of all human ovarian carcinomas, were coupled 
to the surface o f the liposomes. When administered i.p., such 
OV-TL3-immunoliposomes bind rapidly and efficiently (more 
than 80% of the injected i.p. dose) to human ovarian cancer 
cells located in the peritoneal cavity o f nude mice (Nassander 
et al., 1992).
The aim of this was to
immunoliposome-mediated targeting o f DXR to ovarian 
cancer cells translates into an enhanced anti-tumour effcct 
compared with non-targeted DXR-liposomes (lacking the 
antibody). Target cell binding and anti-tumour activity of 
DXR-immunoliposomes were studied in vitro and in vivo. The 
i.p. growing NIH:OVCAR-3 tumour was chosen for in vivo 
evaluation as this model has many features in common with 
clinical disease, including development of abdominal disease, 
ascites formation and expression o f the tumour-associated
OA3 (Hamilton et al., s et a/„
e t ; Boerman et al., 1990). This is the first 
report describing the in vivo anti-tumour activity of DXR-
immunoliposomes in a xenograft of i.p.
ovarian carcinoma.
Materials and methods
Fetal calf serum (FCS) was from Bocknek
Laboratories, Canada. RPMI-1640 medium supplemented
with 25 mM L-glutamine were
from Gibco (Breda, The Netherlands). Dulbecco’s modified
Eagle’s medium (DMEM) was by ICN Flow
(Zoetermeer, Netherlands). F(ab ' ) 2  fragments of the
monoclonal antibody OV-TL3 were donated by Centocor 
EuropeBV (Leiden, The Netherlands). DXR was a gift from 
Pharmachemie (Haarlem, The Netherlands). Egg phosphati­
dylcholine (EPC), cholesterol (CHOL), trichloroacetic acid 
(TCA), dithiothreitol (DTT) and sulphorhodamine-B (SRB) 
were obtained from Sigma (St Louis, MÖ, USA). E«,‘i-
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phosphatidylglycerol (EPG) was a gift from Nattermann liposomes that were not incubated with Fab' fragments are 
Phospholipid GmbH (Cologne, Germany). Phosphatidyletha- referred to as non-targeted liposomes throughout this paper, 
nolamine (PE) was obtained from Nutfield Nurseries Lipid Liposome dispersions were stored at 2 -8 ° C  and used within
Products (Nutfield, UK). Succinimidyl 4-(/;-maleimidophe- 
nyl)butyrate was obtained from Pierce (Rockford, USA). 
[la,2a(n)-JH]Cholesteryl oleyl ether, [U-I4C] sucrose and 
[14-14C]doxorubicin hydrochloride were obtained from 
Amersham (Buckinghamshire, UK). All other reagents were 
of analytical grade.
3 weeks after preparation.
Monoclonal antibody
The murine monoclonal antibody OV-TL3 is directed against 
the OA3 antigen, present on over 90% of all human ovarian 
carcinomas (Poels et a l 1986; Boerman et a l 1990; Massuger 
et al., 1991). F(ab')2 fragments of OV-TL3 were incubated with 
20 mM DTT in acetate buffer at pH 5.5 (100 mM sodium 
acetate, 63 mM sodium chloride, 1 mM EDTA) for at least 
90 min at room temperature (Nassander et al., 1995). DTT was 
removed by applying the incubation mixture onto a Sephadex 
G-25M column (PD-10; Pharmacia, Woerden, The Nether­
lands). Elution occurred with acetate buffer pH 6.5 (100 mM 
sodium acetate, 40 mM sodium chloride, 1 mM EDTA, 
deoxygenated and flushed with nitrogen before use). Fab' 
fragments appearing in the void volume were used immediately 
for covalent attachment to freshly prepared liposomes contain­
ing the anchor molecule N-[4-(p-maleimidophenyl)butyryl] 
phosphatidylethanolamine (MPB-PE).
Liposome characterisation
Lipid phosphate was determined by the colorimetric method of 
Fiske and Subbarow (1925). The amount o f protein coupled to 
the liposomes was determined by the method of Wessel and 
Fliigge (1984), with bovine serum albumin as standard. The 
amount of monoclonal antibody coupled to the liposomes was 
expressed as pig Fab' per ¿¿mol TL. D X R  was determined 
fluorimetrically after destruction of the liposomes with acidified 
ethanol (94% ethanol, 0.3 M hydrochloride acid; excitation 
wavelength 490 nra, emission wavelengths 591nm). Radio­
activity of the liposomal dispersions was assayed with I-Iionic- 
Fluor (Packard instruments, Downers Grove, Illinois, USA) as 
scintillation mixture and counted in a Tri-Carb 1500 liquid 
scintillation counter (Packard Instruments). Mean particle size 
was determined by dynamic light scattering with a Malvern 
4700 system using a 25 mW helium -neon laser and the 
Automeasure version 3.2 software (Malvern, Malvern, UK). 
For viscosity and refractive index the values of pure water were 
used. As a measure o f the particle size distribution of the 
dispersion, the system reports a polydispersity index. This index 
ranges from 0.0 for an entirely monodisperse up to 1.0 for a 
polydisperse dispersion.
was
Preparation o f  immunoliposomes
MPB-PE was synthesised, purified and analysed as described 
above (Martin and Papahadjopoulos, 1982; Nassander et al., 
1995). MPB-PE was incorporated into the liposomal bilayers 
to allow covalent coupling o f Fab' fragments to the liposomal 
surface. The composition of the bilayer o f the liposomes used
EPC:EPG:CHOL:MPB-PE at a molar ratio of 
38.1:4:32:1.9. For cell binding and biodistribution experi­
ments, traces of [3H]cholesteryl oleyl ether were added. A 
mixture of the appropriate amounts of lipids in chloroform 
was evaporated to dryness in a rotary evaporator at 35°C 
under reduced pressure. After flushing the lipid film with 
nitrogen for at least 20 min, the lipid film was hydrated in a 
120 mM ammonium sulphate solution containing 1 mM
(freezing in liquiddesferal. ten freeze -  thaw
nitrogen at — 196°C, thawing at 60°C), the resulting liposome 
dispersion was sequentially extruded through polycarbonate 
membrane filters with 0.6 /¿m and 0.2 jum pore size (Unipore, 
Biorad, Richmond, CA, USA) under nitrogen pressures up to 
0.8 MPa, which resulted in a mean particle size of 
approximately 0.25 ¿on.
The liposomes were loaded with DXR by creating an 
ammonium sulphate gradient as described recently (Haran et 
al., 1993). After extrusion, the external medium of 
liposomes was replaced by a glucose (0.2 m)~ sodium chloride 
(37.5 mM) solution using ultracentrifugation (100 000 xg-, 
45 min). Then, liposomes were incubated with DXR for 
30 min at 40°C (incubation conditions 15 ¿imol total lipid 
(TL) per ml; 1 mg DXR m l-1; 1 mM desferal). Non­
encapsulated DXR was removed using the cation exchange 
resin Dowex 50WX-4 (Storm et al., 1985). The liposomes 
were centrifuged (100 000 x g ,  30 min) and the pellet was 
redispersed in acetate buffer pH 6.5. The freshly prepared 
DXR-liposomes containing the anchor molecule MPB-PE 
were mixed with freshly prepared Fab' fragments (concen­
trations during incubation ranged from 6 —12 /¿mol TL per 
ml and 0 .25-0 .35  mg Fab' per ml respectively). The coupling 
reaction was carried out overnight at 4°C under constant 
rotation in nitrogen atmosphere.
Finally, the DXR-immunoliposomes were separated from 
unconjugated Fab' fragments by ultracentrifugal sedimenta­
tion at lOOOOOx# for 30 min. The pellet was resuspended 
and washed twice with Hepes buffer (20 mM Hepes, 149 mM 
sodium chloride, 1 mM EDTA, pH 7.4). MPB-PE-containing
Tumour cell line
The human ovarian cancer cell line NIH:OVCAR-3 
originated from Dr TC Hamilton (Hamilton et al., 1983, 
National Cancer Institute, Bethesda, MD, USA). The 
NIH:OVCAR-3 cells were maintained in DMEM supple­
mented with heat-inactivated FCS (10%), glutamine (2 mM), 
penicillin (100 units m l"1), streptomycin (100 ¿¿g m l 1) and 
amphotericin B (0.26 ¡.tg m l~ ‘).
In vitro cell growth inhibition
In vitro cell growth inhibition was determined by the SRB 
assay which involves the measurement o f cellular protein, 
using the dye sulforhodamine-B (SRB) (Rubinstein et al..
1990; Skehan et al., 1990). 
cultured as monolayers
, ovarian tumour cells 
with trypsin/EDTA
(0.05%/0.02%) and washed with medium. Subsequently, cells 
(4 x 1 0 s m l 1) were incubated in suspension for 30 min at 
37DC with DXR-immunoliposomes, non-targeted DXR-
*s or free DXR. After the incubation, unbound 
liposomes and remaining free DX R  were removed by
gation (500 x g ,  3 min). The cell pellet was was 
twice and resuspended in culture medium. Then, 4 x  10‘‘ cells
in a flat bottom 96-well plate ■<.per well
cultured for 72 h at 37“C and 5% ide. The
cultures were fixed with 5% trichloroacetic acid (TCA) at 4"C 
for 1 - 2  h, washed with water and finally stained with 0.4% 
SRB dissolved in 1% acetic acid. After 20 min, the plates 
were washed with 1% acetic acid and air dried. The bound 
dye was dissolved in 10 mM Tris and the optical density was 
measured at 490 nm using a Biorad novapath microplate 
reader (Biorad Laboratories, Veenendaal, The Netherlands). 
The cytotoxic activity o f DXR is expressed as relative cell 
growth, which is defined as the degree o f cell proliferation 
relative to that of non-treated cells ( =  100%) and is presented 
as IC,(„ i.e.the DXR concentration that induces 50% 
growth inhibition compared with non-treated cells.
7tg o f  D X R -i somes to ovarian cancer cells in
vitro
In vitro cell binding o f DXR~(immuno)liposomes was s
using DXR-li 
ether. OVCAR-3
as containing -’H-la sd cholesteryl oleyl
s were harvested as described above and
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incubated with the radiolabelled liposomes at 37°C for 30 or 
90 min under the following conditions: 4 x  10s cells m l-1, 0 -
Unboundi0 .8 8 /imol T L m l-1 and 0 —14 /¿g D X R  ml' 
liposomes were separated from the cells by centrifugation 
(500 x# , 5 min). The cell pellet was washed twice with 
medium, mixed with 1 ml Soluene-350 (Packard) and 
digested at 40°C overnight. Radioactivity was measured as 
described above.
The amount of DXR associated with OVCAR-3 cells was 
studied by fluorescence analysis. OVCAR-3 cells (1 x 105 
cells ml-1) were incubated in suspension at 37°C for 30 min 
with DXR-immunoliposomes or non-targeted DXR-lipo­
somes at a DXR concentration of 125 j.ig m l~!. Unbound 
liposomes were separated from the cells by centrifugation 
(500 x g ,  5 min). The cell pellet was washed twice with ice- 
cold medium, resuspended in 0.5 ml 0.25% paraformalde­
hyde in PBS and kept on ice until fluorescence was measured. 
Fluorescence analysis was performed using a single laser 
FACScan, at a wavelength >  650 nm (Becton and Dickinson 
Immunocytometry Systems, Mountain View, CA, USA).
Animals and tumour model
NMRI athymic nude mice (Rygaard and Friis, 1974) were 
bred at Harlan CPB (HsdCpn:NMRI-rcw, Zeist, The 
Netherlands). The animals were housed throughout the 
experiment under specified pathogen-free conditions in 
sterile filter-top cages. They received sterile standard food 
(SRM-A, Hope Farms, Woerden, The Netherlands) and 
acidified sterile water ad libitum. At the start o f  the 
experiment the animals were 5 -1 0  weeks old.
The tumour cell line NIH:OVCAR-3 was propagated 
intraperitoneally as described earlier (Nassander et al., 1992). 
At 3-week intervals ascites was harvested from the donor 
animals by rinsing the peritoneal cavity with plain RPMI- 
1640 medium. Cells were centrifuged once (500x g ,  5 min) 
and resuspended in plain RPMI-1640 medium at a 
concentration of approximately 4 x l 0 7 vital cells m l-1 
(vitality determined by trypan blue dye exclusion); 0.5 ml of 
this cell suspension was injected i.p. per mouse. The nude 
mice developed a reproducibly growing ascitic tumour with 
only minor solid tumour growth.
light ether anaesthesia blood samples were drawn from the 
retroorbital plexus into heparinised tubes. Then, the mice 
were sacrificed and the peritoneal cavity was rinsed with 
4 x 5  ml PBS. Samples for determination of the total 
amount of radioactivity present in the peritoneal cavity 
were drawn immediately. Subsequently, the peritoneal cell 
suspension was centrifuged (500 x g ,  5 min) to spin down 
the cells. The supernatant was collected and samples were 
drawn to determine the amount o f radioactivity present in 
the peritoneal cavity, not associated with tumour cells. 
Liver and spleen were collected and weighed. Radioactivity 
in blood was determined after the addition o f Plasmasol 
(Packard) and decolorisation with 30% hydrogen peroxide 
at 40°C 
Plasmasol as
Radioactivity was assayed with
Blood volume was
body weight (Wish et al., 1950).
scintillation mixture, 
taken as 77.8 ml kg"'1 
Samples o f peritoneal washings, supernatant, liver and
were digested by the addition o f Soluene-350 
(Packard) and incubation at 40°C overnight, yielding clear 
solutions. Radioactivity was assayed with Hionic-Fluor
were(Packard) as ation mixture. All
counted as described above (see liposome characterisa­
tion). Radioactivity levels measured were converted to the 
percentage of the injected i.p. dose. The percentage of 
liposomes bound to the OVCAR-3 cells was calculated by 
subtracting the percentage of radioactivity present in the 
supernatant from the percentage o f the radioactivity present 
in the peritoneal washings before centrifugation. The 
integrity o f the liposomes with respect to release o f the 
aqueous contents was calculated by comparing the ratio of 
the readings for the aqueous marker [l4C]sucrose and the 
lipid label [3H]cholesteryl oleyl ether before and 
injection.
To study the biodistributrion of the encapsulated drug, 
trace amounts o f [14C]DXR were incorporated in DXR- 
immunoliposomes. [14C]DXR-immunoliposomes and non- 
targeted [14C]-DXR-liposomes (2 ¿imol TL and 175 /tg DXR  
per mouse, i.e. about 6 mg DXR kg 1) were administered i.p. 
on day 7 after tumour cell inoculation. To study the fate of 
the free drug in the peritoneal cavity, free [,4C]DXR (40 fj,g 
per mouse, i.e. about 1.5 mg DXR kg ') was administered 
i.p. on day 21 after tumour cell inoculation. At different time 
points after injection the animals were sacr
In vivo anti-tumour activiti was
n
/
Animals were treated 7 days after tumour cell inoculation 
with a single i.p. injection of DXR-(immuno-)liposomes at 
a dose of 0 -  18 mg DXR kg 1 and 0--330 /¿mol TL kg ' in
tumour cella volume of 0.5 ml. 
inoculation, the animals were sacrificed and the peritoneal 
cavity was rinsed with PBS to collect all free-floating cells. 
Cells were centrifuged (500 x g ,  5 min) and the pellet weight 
was determined. The weight of the collected tumour cells 
was used as a parameter for the anti-tumour response.
In vivo distribution studies
Double-radiolabelled immunoliposomes were used to study 
the biodistribution of the immunoliposomes after i.p.
administration. [:’H]cholesteryl oleyl
marker of the lipid phase. The aqueous phase was labelled 
with [l4C]sucrose to study the integrity o f the liposomes
The effect o f different treatments was c
Student’s /-test assuming equal vark 
fidence interval. Differences wer 
P-value of comparison was <0.05.
ard by a two-tail 
with 95% con-
Rcsults
In vitro cell growth inhibition
OV-TL3-immunoliposomes containing DXR were investi­
gated for their cell growth inhibition effect towards in vitro
ofcultured ovarian cancer In series
was used as a experiments, monolayers of cells were incubated with free
D X R  or DXR-(immuno)liposomes. However, only minor c
growth inhibition was owing to
with respect to release of the encapsulated aqueous contents binding of immunoliposomes (data not shown). To improve
■  -  .a  . . . .  A  4m . a
peritoneal cavity. It was shown that i.p. the ri'Pi'
[14C]sucrose is cleared from the peritoneal cavity 
within 2 h (Nassander et al., 1992). The uptake in blood.
to mimic a more
and 5 h was shown to be very low
were incubated with the tumour
growth inhibition of DXR-immunoliposomes 50
(0.03 ±0.01; 0.15 ±0.04; 0.01 ±0.00%  of the
Liposomes were administered i.p. to mice bearing the 
OVCAR-3 tumour on days 7, 14 and 21 after tumour cell 
inoculation. Five hours after injection the radioactivity in 
peritoneal washings, blood, liver and spleen was determined 
as described before (Nassander et al., 1992). Briefly, under
32 ± 2  ¡a m ) was in the same range as that o f free DXR  
(ICso 19 ± 6  /¿M). The in vitro cell growth inhibition of non-
DXR-lipsomes (lacking the antibody) was clearly 
inferior (ICJ0 630 ±  100 /¿M) to that o f the DXR-immunolipo-
= 6 x 10 s). Empty immunoliposomes did notsomes (P -
influence the cell growth at the relevant lipid concentrations 
used.
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or the wall of the peritoneal cavity. No metastatic tumour 
In vitio cell binding growth could be detected within the liver, spleen, kidneys,
To investigate whether the cell growth inhibition of DXR- intestines and lymph nodes (superior mesenteric, iliac) or in
immunoliposomes requires binding of the immunoliposomes tissues outside the peritoneal cavity, e.g. lungs and the
t  ^  *  *
to the tumour cells, radiolabelled DXR-immunoliposomes 
were prepared. In the lipid bilayer of the liposomes
parathymie and mediastinal lymph nodes.
On day 7 after tumour cell inoculation i.p. treatment was
[3H]cholesteryl oleyl ether was incorporated. This label does started with DXR-liposomes with and without coupled
not exchange with proteins and is not hydrolysed in cells and tumour-specific OV-TL3 Fab' fragments. The anti-tumour
is therefore a useful marker to study cellular association o f effect was determined on day 21 after tumour cell inoculation,
liposomes (Stein et a l ,  1980; Pool et a l 1982). Figure 1 shows Untreated mice showed progressive tumour growth (Figure 3).
that immunoliposomes bound to the tumour cells to a higher The dose-response study reveals a dose-dependent inhibition
extent ( 9 .5 - 13-fold) than non-targeted liposomes, which of tumour growth. However, no difference in anti-tumour effect
showed hardly any binding. The degree o f cell binding of between treatment with DXR-immunoliposomes and non-
-  _ »  __a .  -  - A  J  i
targeted DXR-liposomes was observed. At the lowest dose 
(0.67 mg DXR kg ‘) examined, both types of DXR-liposomes
already induced substantial 
(P  < 2 x 1 0  - 5
tumour growth inhibition
v.y control). A nearly complete inhibition of 
tumour growth was obtained at dose levels > 2  mg kg-1.
the tumour-specific DXR-immunoliposomes increased in time 
and appeared to be dependent on the liposomal lipid 
concentration used. It was estimated that at the highest lipid 
concentration used about 7000 immunoliposomes were 
binding to one tumour cell after 90 min of incubation. A 
separate flow cytometry (FACS) experiment confirmed the Microscopic differentiation showed that when the determined 
need to have a tumour-specific antibody on the external tumour load was less than 0.5 g, other cells (e.g. lymphocytes) 
liposome surface for obtaining cell binding. The mean rather than viable tumour cells were responsible for the 
fluorescence per cell was 15-fold higher after incubation of determined weight.
OVCAR-3 cells with DXR-immunoliposomes compared with
non-targeted DXR-liposomes [mean fluorescence 1100 and 70 
respectively; blank value (and empty immunoliposomes) about In vivo distribution o f  immunoliposomes
20]. DXR levels might be underestimated owing to the fact To investigate why tumour-specific DXR-immunoliposomes
___ A . ^
that DXR-fluorescence is quenched when bound to DNA.
In vivo anti-tumour activity o f  DXR-immunoliposomes
Stimulated by the superior cell growth inhibition observed in 
vitro, the anti-tumour activity o f the tumour-specific DXR- 
immunoliposomes was tested in athymic mice bearing i.p. an 
ascitic OVCAR-3 tumour. Nude mice developed intraper- 
itoneal disease after an i.p. injection of 2 x l 0 7 OVCAR-3 
cells. The OVCAR-3 cell line grew as single cells or as cell 
clusters in ascites. Solid tumour nodules remaining in the 
peritoneal cavity after collecting the ascitic cells were 
primarily detected in the lesser sac. As shown in Figure 2,
weight of the solid tumour mass was smallthe
compared with the weight of the ascitic tumour cells (over 
4 g on day 21) and increased from 0.1 to about 0.4 per mouse 
over a 2-week period. The tumour did not invade the organs
are not more efficacious in vivo than non-targeted DXR- 
liposomes, the degree o f binding o f immunoliposomes to the 
peritoneal tumour cells was determined. These experiments 
were performed with double-radiolabelled liposomes. 
[3H]Cholesteryl oleyl ether was used as a marker of the 
liposomal lipid phase. In addition, [l4C]sucrose was 
incorporated in the internal aqueous phase to study the 
integrity o f the liposomes. Double-radiolabelled immunolipo­
somes and non-targeted liposomes were administered i.p. to 
OVCAR-3-bearing nude mice at different times (day 7, 14 or 
21) after tumour cell inoculation. On all days of examination, 
the cell binding of immunoliposomes was much higher 
compared with non-targeted liposomes (see Table I). About 
5% of the injected 3H-liposomal dose was found in spleen,
liver and blood, 5 h injection. The integrity of the
«
Oo
too
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o
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o
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lipovsomes with respect to release of the aqueous contents was 
also investigated. Release o f  sucrose from the liposomes will 
be detected as an increase in the iH /14C ratio of the injected 
liposome preparation. It was calculated that the loss of 
sucrose label from both immunoliposomes and non-targeted
peritoneal cavity was minimal
( <  15% ) indicating that
rem: intact
bilayer 
not
5
4
3
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Figure 1 In vitro 
OVCAR-3 cells
(O and
cell binding o f DXR-immunoliposomes, 
were incubated with DXR-immunoliposomes 
) or unconjugated DXR-liposomes ( □  and ■ )  for 30 
(O , □ )  or 9 0 min ( # ,  ■ )  at 37"C. After washing the cells to 
remove unbound liposomes, cell-associated radioactivity was 
determined as described under Materials and methods. The 
degree o f  cell binding is expressed as the estimated amount of 
liposomes (nmol TL) bound per 106 cells. The Fabyiipid ratio of  
the immunoliposomes was 12^g OV-TL3 per /¿mol TL. The 
outcome of a representative experiment is shown.
0 "ii&l *» LlLW ^
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c 1 « rv  A  '  W 111 -»•-1
Day 7 Day 14 Day 21
2 Growth of OVCAR-3 in NMRI nude mice. Mice were 
injected i.p. with 2 x  107 OVCAR-3 cells (day 0). At days 7, 14 
and 21 after tumour cell inoculation, mice were sacrificed for 
determination of tumour load [ascitic tumour cells ( 1 3  ) and
solid tumour ( C__j )]. Values represent the mean tumour
load±s.d . of 8 -12 animals.
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Figure 3 Effect of DXR-immunoliposomes on growth of  
OVCAR-3 ovarian carcinoma in vivo. OVCAR-3 tumour-bearing 
athymic nude mice were treated with a single i.p. injection on day 
7 after tumour cell inoculation. DXR-immunoliposomes ( I 1) 
or unconjugated DXR-liposomes (E H ) were administered in a 
volume of about 0.5 ml. Control mice received PBS. The i.p. 
tumour load was determined on days 21 and 22 after tumour cell 
inoculation. Values represent the mean tumour load o f 3 - 4  
animals; for the untreated group six animals were used. The FabV 
lipid ratio of immunoliposomes was 20 ¡xg OV-TL3 per /¿mol TL. 
When the tumour load was less than 0.5 g, the determined weight 
was mainly caused by cells other than tumour cells (e.g. 
lymphocytes).
To investigate the question, whether the fate o f the drug, 
doxorubicin, parallels the fate o f the liposomes, the 
(immuno)liposomes were labelled with [14C]DXR and 
administered i.p. on day 7 after inoculation of the 
OVCAR-3 cells. Radioactivity associated with the tumour 
cells was determined 5 h and 24 h after injection. As shown 
in Table II, the percentage cell-bound [l4C]DXR was not
administration of non-targeted 
[l4C]DXR-liposomes or [14C]DXR-immunoIiposomes. Appar-
ently, non-ti liposomes are as as the
immunoliposomes in the of DXR to the cancer
cells. The extent o f D X R  associated with the tumour cells 
after administration o f non-targeted [l4C]DXR-liposomes was 
much higher than expected on the basis o f the levels of cell- 
associated liposomal 3H label (see Tables 1 o 
observation suggested to us that part of the tumour
l4C-DXR must be attributed to
ind II). This
assocu
[l4C]DXR
tumour
liposomes. To 
D X R  to
from the
binding of free  the peritoneal 
was also examined. Free [l4C]DXR was 
administered i.p. in ascitic OVCAR-3 tumour-bearing mice 
on day 21 after tumour cell inoculation. Figure 4 shows that 
[l4C]DXR is disappearing from the peritoneal cavity at a slow 
rate. Even 24 h after injection o f [14C]DXR 29 ±4%  of the 
injected dose was recovered from the peritoneal cavity. In line 
with the earlier suggestion, most of the injected amount of  
DXR appeared to be associated with the OVCAR-3 cells.
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Table II Doxorubicin levels associated with peritoneal OVCAR-3 
cells after i.p. administration of [l4C]DXR-immunoliposomes
Injected ,4C-D XR  dose ( % )  associated
wih the tumour cells
Time after Unconjugated Immuno-
administration (ft) liposomes liposomes
5 52 rfc 2 58 ± 7
24 34 ± 8 35 ± 2
[l4C]-DXR-(immuno)liposomes were administered i.p. into athymic 
nude mice on day 7 after tumour cell inoculation. Radioactivity was 
determined 5h  and 24 h after administration as described under
Materials and methods. The Fab'/lipid ratio o f the immunoliposomes 
was 19 ¡xg OV-TL3 per /miol Tl. The mean tumour load was 1.3 ±  0.3 g. 
Data represent the mean ±  s.d. o f  live animals.
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Figure 4 Recovery o f free 14C-DXR in the peritoneal cavity of  
OVCAR-3-bearing nude mice. I4C-DXR (40 fig per mouse, i.e. 
approximately l .5 mg D X R k g -1 ) was administered i.p. on day 21 
after tumour cell inoculation in a volume of 0.5 ml. Results are 
expressed as the % o f the injected dose ,4C-DXR present in the 
peritoneal cavity (O ) and associated with tumour cells ( # ) .  
Values represent the mean tumour load of 4 - 5  animals.
Discussion
The study presented in this paper is concerned with the use of 
immunoliposomes (antibody-targeted liposomes) as carriers
for doxorubicin (DXR) for i.p. chemotherapy of ovarian
carcinoma. As a prelude to assessing anti-tumour activity
of DXR-containing OV-TL3 immunoliposomes towards in
vivo growing human ovarian cancer (OVCAR-3), we first
* f n 1« f i* to c
binding of DXR-immunoliposomes towards in vitro 
OVCAR-3 cells. The in vitro cell growth inhibition o f DXR  
encapsulated in immunoliposomes was far (200-lbld) superior
to DXR in ar non-ta re
antibody fragments), 
of the free drug. In line with 
results, effective tumour cell binding was obtained with OV-
TL3 DXR-immunoliposomes 
DXR-liposomes. The
not with non-targeted 
data are in the same
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Table I Effect o f  i.p. tumour load on the degree o f tumour cell binding of immunoliposomes
«1« ■ —wk — — w mu * > i'iuUhj
Tumour load (g )  Injected 3H dose ( % )  associated with the tumour cells
Day after tumour cell inoculation Unconjugated liposomes Immunoliposomes
A* ■ 111 1 m l  n %% ‘r  . - - ‘ — i  -  |  . j  —  -  .  ------— (—-  ------- - - » N - f - 'm  M " ' n l  'R i fe r ì  '  v « i « * «  • I . . . .  .  . — \  ». )  , • * , .#  . J i  —  •  f « —^  * * * • ! •  U U  ........... .. I  1.*^* .••...•*^ «1 4 ■ « A m a  ■ ■ ■ up *| ■ “ *“ ! * “ * ► < ■ 1 » 11 » /* * * • '■*■* *  \  — *  1 ^  •  •  . A .  L. ■; -y-, ^  •  i  I ^  *  *  -  *  ,  .  1^1 • ^  I M l  ^  ~i '
1.0 ±0.1 (day 7)
2.1 ± 0 A  (day 14) 
4.6 ±0 .4  (day 21)
17 ±  10 42 ±  13*
6 ±  3 74-1-6**
6 ±  I 8 8 ±  13**
“I
(Immuno)liposomes containing [‘ H]-cholesteryl oleyl ether were injected i.p. into athymic nude mice, 7, 14 or 
21 days after tumour cell inoculation. Radioactivity was determined 5h after administration as described under 
Materials and methods. The Fab'/lipid ratio of the immunoliposomes was 3 0 /ig OV-TL3 per jumol TL. Data 
represent the mean ± s.d. of 4 -  6 animals. *P<0.05; **ƒ*<0.0001 (immunoliposomes vs unconjugated liposomes 
on the same day after tumour cell inoculation).
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1 0 2 8
range as those reported earlier obtained in cell binding After cell binding of immunoliposomes, the encapsulated 
experiments with OV-TL3 immunoliposomes without DXR drug can enter the cell via different routes. Firstly, the 
(Niissander et al., 1995), indicating that inclusion of DXR
does not interfere with the cell binding of immunoliposomes.
As the combined in vitro results on target cell binding and
immunoliposomes can be taken up by endocytosis. However, 
Niissander et al. (1995) showed that internalisation by these 
tumour cells takes place only to a low degree. Secondly, the 
cytotoxicity of DXR-(immuno)liposomes strongly suggest that liposomal contents can be released slowly after tumour cell 
specific binding to the cells is conferring greater tumour 
cytotoxicity, studies were initiated to evaluate the i.p. anti­
tumour effects in vivo. The i.p. growing OVCAR-3 tumour was 
used because of resemblance to human in situ ovarian 
carcinoma in terms of morphology, histology and synthesis of a more important role in the mechanism of DXR uptake in
binding, providing high DXR concentrations near the 
tumour cell surface. The results presented in this paper 
indicate that premature drug leakage occurring before 
binding of the immunoliposomes to the tumour cells plays
tumour-specific antigens (Hamilton et al., 1984). The 
characteristics o f ovarian carcinoma, i.e. it usually remains 
within the peritoneal cavity and rarely disseminates to distant 
body sites, were confirmed. In an earlier study we reported that
this tumour model than leakage from cell-bound immuno­
liposomes. One way to improve the situation for DXR- 
immunoliposomes in this model is to prevent premature drug 
leakage by manipulation of the lipid bilayer composition. By
OV-TL3 immunoliposomes bind rapidly and efficiently (over the selection of phospholipids with higher phase transition
temperatures, more stable DXR-liposomes can be prepared. 
However, the more rigid DXR-immunoliposomes were not 
nearly as effective as free DXR and the more fluid-type 
observed degree of tumour cell binding is dependent on the immunoliposomes used in this study (results not shown). This
80% of the injected dose on day 21 after tumour cell 
inoculation) in this xenograft model. In vivo target cell binding 
experiments confirmed these data and showed that the
day of administration (i.e. the tumour load). As shown in 
Figure 3, both DXR-immunoliposomes and non-targeted 
DXR-liposomes induced a pronounced anti-tumour effect. 
However, no difference in anti-tumour activity between the 
targeted and non-targeted formulation was observed. Thus, 
despite the observation of specific binding o f the immunolipo­
somes to the tumour cells, differences in anti-tumour response 
exerted by the DXR-immunoliposomes and non-targeted 
DXR-liposomes were observed only in vitro and not in vivo. 
One likely explanation for this discrepancy is the occurrence of 
considerable drug leakage from the administered specific and 
non-specific DXR-liposomes induced by the peritoneal 
environment. Rapid, premature drug loss may have over­
shadowed the occurrence of specific immunoliposome- 
mediated anti-tumour effects. Studies with radiolabelled 
DXR showed that practically all DXR recovered from the 
peritoneal cavity was associated with the tumour cells after i.p. 
administration of free DXR (Figure 4). Likewise, DXR leaked 
from DXR-immunoliposomes or non-targeted DXR-lipo­
somes present in the peritoneal cavity will rapidly associate 
with the tumour cells. The observation that the non-targeted 
liposomes, which show little cell binding, are able to deliver as 
much DXR to the target cells as the specific immunoliposomes 
(Table II) strongly indicates that a large part of the liposomal 
DXR content is rapidly lost from the non-targeted liposomes. 
Considering the identical lipid composition, it is reasonable to 
assume that the extent o f DXR leakage was similar for the 
targeted liposomes. Therefore, leakage and subsequent rapid 
association with the tumour cells is likely to explain the absence 
of any differences in anti-tumour response exerted by the 
immunospecific and non-specific DXR-liposomes and makes it 
difficult to discriminate between DXR anti-tumour activity 
induced by cell-bound and non cell-bound liposomes. The fact 
that differences in tumour cell growth inhibition were observed 
in vitro and not in vivo probably relates to the different 
composition of the incubation medium compared with ascites 
and the much shorter incubation time (30 min) compared with 
the long residence time in the peritoneal cavity o f the mice.
Considering that the majority of the injected DXR  
molecules associate rapidly with the OVCAR-3 cells after 
i.p. injection, it is clear that the anti-tumour activity of free 
DXR is not easily improved by (immuno)liposome-mediated 
delivery. Other cytostatics with less affinity for the tumour 
cells should be considered as more promising candidates for 
immunoliposome-mediated delivery in this tumour model.
would indicate to us that cell-bound rigid immunoliposomes 
do not sufficiently release the encapsulated drug. To improve 
the therapeutic availability of the entrapped drug, triggered 
destabilisation of cell-bound rigid immunoliposomes seems a 
better option. After binding o f stable DXR-immunolipo- 
somes to the tumour cells and clearance o f unbound DXR- 
liposomes from the peritoneal cavity, destabilisation by, for 
example, raising the temperature (then temperature-sensitive 
liposomes should be used, e.g. Yatvin et al., 1978; Maruyama 
et a l ,  1993), or lowering the pH (pH-sensitive liposomes, 
reviewed by Torchilin et al., 1993) might lead to efficient 
tumour cell kill.
In summary, the in vitro cell growth inhibition of DXR 
encapsulated in OV-TL3 immunoliposomes is superior to 
that of non-targeted DXR-liposomes (lacking the specific 
antibody). In tumour-bearing nude mice, however, no 
difference in anti-tumour effect could be determined between 
targeted and non-targeted DXR-liposomes. Our results 
indicate that premature DXR leakage from (immu- 
no)liposomes and subsequent DXR association with the 
tumour cells, explains why no significant differences in anti­
tumour activity between DXR-immunoliposomes and non- 
targeted DXR-liposomes were observed. Further experiments 
will be focused on the in vitro and in vivo evaluation of stable, 
temperature-sensitive liposomes, which rapidly release their 
contents upon raising the temperature to about 42°C.
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DTT, dithiothreitol; DXR, doxorubicin; EPC, egg-phosphatidyl- 
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Hepes, 4-(2-hydroxyethyl)-l-piperazineethanesulphonic acid;
MPB-PE, N-[4-(p-maleimidophenyl)butyryl] phosphatidylethanol- 
amine; PBS, phosphate-buffered saline; PE, phosphatidylethanol- 
amine; SRB, sulforhodamine-B; TCA, trichloroacetic acid; TL, 
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